Abiraterone Acetate Prolongs Survival in Metastatic Prostate Cancer
the Cancer Therapy Advisor take:
COU-AA-302 trial was conducted earlier in 2013 to evaluate whether abiraterone acetate, an androgen biosynthesis inhibitor, improved overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy.
The planned interim analysis from the trial showed that abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone. Recently, a placebo-controlled, double-blind, randomized study, presenting presepecified final analysis of the COU-AA-302 trial, was published.
The objective of the study was to assess the effect of abiraterone acetate plus prednisone on overall survival, time to opiate use, and use of other subsequent therapies.
There were 1,088 patients in the study who were asymptomatic or mildly symptomatic with chemotherapy-naïve prostate cancer. Patients were randomly assigned to receive either abiraterone acetate plus prednisone (abiraterone acetate group), or placebo plus prednisone (placebo group). Of the prespecified 773 death events for the final analysis, 65% of patients in the abiraterone acetate group experienced death events and 71% in the placebo group.
Results showed that the median overall survival was significantly longer in the abiraterone acetate group than in the placebo group (34.7 months [95% CI 32.7-36.8] versus 30.3 months [28.7-33.3]; hazard ratio 0·81 [95% CI 0.70-0.93]; p=0·0033).
Subsequent treatment with one or more approved agents was used in 67% of patients in the abiraterone acetate group and 80% in the placebo group. Among the patients in the placebo group, 44% subsequently received abiraterone acetate therapy.
Overall, the authors concluded that abiraterone acetate significantly prolonged overall survival compared to prednisone monotherapy in the treatment of chemotherapy-naive metastatic castration-resistant prostate cancer. The clinical and statistical significance supports a favorable safety profile for abiraterone acetate.
Abiraterone acetate improved overall survival in patients with metastatic castration-resistant prostate cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Immunotherapy in Glioblastoma: Peaks and Pits
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed